Cardiovascular medications

Anti-hypertensives

In general, continue these anti-hypertensive medications on morning of surgery.

ACE inhibitors / ARBs

These should be continued as normal pre-operatively.

Examples:

  • ACEi: Captopril, Enalapril, Fosinopril, Imidapril, Lisinopril, Perindopril, Quinapril, Ramipril, Trandolapril
  • ARB: Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan
  • Combination: Valsartan/Sacubitril (Entresto®)

Beta blockers

Continue beta-blocker medications pre-operatively. For patients on sotalol, check potassium and magnesium levels pre-operatively if a U&E is indicated1.

Examples: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Carvedilol, Celiprolol, Labetalol, Levobunolol, Metoprolol, Nadolol, Nebivolol, Pindolol, Propranolol, Sotalol, Timolol

Calcium channel blockers

Continue calcium channel blocking drugs as normal.

Examples: Dihydropyrodines: Amlodipine, Felodipine, Lacidipine, Lercanidipine, Nicardipine, Nifedipine, Nimodipine, Diltiazem, Verapamil

Vasodilators

These should be continued as normal pre-operatively.

Examples: Hydralazine, Minoxidil

Diuretics

Loop diuretics

Loop diuretics should be held on the morning of surgery unless the patient has heart failure and gentle physical activity causes fatigue, palpitations, or dyspnoea (i.e. METS < 4 due to heart failure)

This includes certain combinations (below).

Examples: Bumetanide, Furosemide, Torasemide, Bumetanide + Amiloride, Co-amilofruse, Furosemide + Spironolactone, Furosemide + Triamterene, Furosemide + Potassium Chloride

Potassium-sparing

Continue these drugs in the pre-operative period, even if part of a combination.

Examples: Amiloride, Eplerenone, Spironolactone, Triamterene, co-amilofruse, co-amilozide, amiloride + bumetanide, spironolactone + furosemide, Kalspare®, amiloride + hydrochlorothiazide + timolol, co-flumactone, co-triamterzide

Thiazides

Continue these drugs in the pre-operative period.

Examples: Bendroflumethiazide, Chlorthalidone, Hydrochlorothiazide, Indapamide, Metolozone, Xipamide, bendroflumethiazide + timolol, co-tenidone, Kalspare®, co-amilozide, hydrochlorothiazide + timolol + amiloride, co-flumactone, co-triamterzide

Combination products

Consideration should be given to prescribing the components of combination products as separate medicines perioperatively, but in generalk these drugs should be continued as normal.

Anti-arrhythmics

Class III

These should be continued as normal pre-operatively.

Examples: Amiodarone, Dronedarone

Glycosides

These should be continued as normal pre-operatively.

Example: Digoxin

Anti-anginal

Ivabradine

This should be continued as normal pre-operatively.

Nicorandil

This should be continued as normal pre-operatively.

Ranolazine

This should be continued as normal pre-operatively.

Other

Statins

Continue these in the pre-operative period. If patients are for major vascular surgery, statins should ideally be started at least 2 weeks pre-operatively2.

Examples: Atorvastatin, Fluvastatin, Pravastatin, Rosuvastatin, Simvastatin

Ezetemibe

This should be continued as normal pre-operatively.


Haematology

Background

The following represents an integration of best perioperative practice but should be integrated with any local documents that might apply. For further information, The Beacon Hospital has the following documents available on the Q-pulse system:

  • “Pre-op management of anti-coagulation and anti-platelet drugs” (doc. no PPC-ORG-203)
  • “Management of direct oral anticoagulants (DOACs)” (doc no. PPC-ORG-204)

Should any questions arise regarding anticoagulants that are not covered by this guide, the above documents should be referred to directly.

If there is any conflict between this guideline and instructions that have been given to the patient, the advice of their specialist takes precedence. It is also advised that the opinion of their consultant surgeon should be sought in the case of such a conflict.

Anti-platelet medications

Aspirin

CARDIAC SURGERY

Alterations to aspirin in this context should be the result of discussions of a multi-disciplinary team including the patient’s surgical, cardiology, and anaesthetic teams3.

NON-CARDIAC SURGERY

  • high dose (≥150mg OD): Consider reducing to low dose (75mg OD) for 7 days pre-operatively (bleeding risk is lower with 75mg-150mg doses and antithrombotic impact is comparable to higher doses4).

  • Low dose (≤150mg): Continue this medication pre-operatively EXCEPT

    • procedures associated with high risk of bleeding or complications of bleeding5:
    • spinal surgery
    • ophthalmological procedures
    • neurosurgical procedures (craniotomy, transphenoidal procedures)
    • individuals who refuse blood transfusion for religious reasons (e.g. Jehovah’s Witness). In this case a consuktant cardiologist should be involved.

ADP Receptor Antagonists

Elective invasive surgery should not be performed on patients who are taking ADP-receptor antagonists. See below for specifics:

CARDIAC SURGERY

Alterations to ADP-receptor antagonists in this context should be the result of discussions of a multi-disciplinary team including the patient’s surgical, cardiology, and anaesthetic teams3.

NON-CARDIAC SURGERY

  1. If patient has had coronary stenting in the past, or a stroke within the previous 3 months, discuss with pre-operative anaesthetist.
  2. Invasive surgery should not be performed whilst the patient is taking an ADP-receptor antagonist. If a patient is taking one of these drugs, they should be stopped 5-7 days pre-operatively, and aspirin 75mg OD should be taken in its place.

Examples: Clopidogrel, Prasugrel, Ticagrelor

Dual Antiplatelet Therapy (DAPT)

Many patients who are receiving DAPT will be doing so for a specified period of time. These patients are likely to be at high risk of thrombosis, so premature discontinuation if DAPT may lead to significant harm.

The first step in deciding how to proceed is to determine if the patient is at high risk if altering DAPT.


Pre-operative DAPT alteration


Dypyridamole

Continue this medication pre-operatively, including combination products.

Except procedures associated with high risk of bleeding or complications of bleeding5: - spinal surgery - ophthalmological procedures - neurosurgical procedures (craniotomy, transphenoidal procedures)

In these cases, consider stopping the day before surgery (see Further Information).

Example: Molita® – contains dipyridamole 200mg and aspirin 25mg

Anti-coagulants

The key aspect of managing anti-coagulation around surgery is striking a balance between the risk of thrombosis (in the absence of anti-coagulation) and the risk of bleeding (in the presence of anti-coagulation).

The two main classes of anticoagulation are:

  1. Coumadins

    • Warfarin
  2. Dorect Oral Anti-Coagulants (DOACs)

    • Rivaroxaban, Apixaban, Edoxaban, Dabigatran

The key issue here is in determining:

  • how long should the anticoagulant be on hold for pre-operatively (i.e. for how long should the patient not take it)?

  • does the patient need to be bridged with low molecular weight heparin whilst the anticoagulant is on hold?

Doing this requires knowledge of the indication as to why the patient is taking the medication, the underlying thrombotic risk if the patient is not on anticoagulation, and the patients renal function.

This can be complex, so it is not covered in detail in this section. It is expanded upon in a section about anticoagulation, which can be found here, or located at the far right of the navbar at the top of this webpage.

References

1.
Wijeysundera DN, Duncan D, Nkonde-Price C, et al. Perioperative beta blockade in noncardiac surgery: A systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: A report of the american college of cardiology/american heart association task force on practice guidelines. Circulation. 2014;130(24):2246-2264.
2.
Members AF, Kristensen SD, Knuuti J, et al. 2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management: The joint task force on non-cardiac surgery: Cardiovascular assessment and management of the european society of cardiology (ESC) and the european society of anaesthesiology (ESA). European heart journal. 2014;35(35):2383-2431.
3.
Ferraris VA, Saha SP, Oestreich JH, et al. 2012 update to the society of thoracic surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. The Annals of Thoracic Surgery. 2012;94(5):1761-1781.
4.
Koenig-Oberhuber V, Filipovic M. New antiplatelet drugs and new oral anticoagulants. BJA: British Journal of Anaesthesia. 2016;117(suppl_2):ii74-ii84.
5.
Members AF, Kristensen SD, Knuuti J, et al. 2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management: The joint task force on non-cardiac surgery: Cardiovascular assessment and management of the european society of cardiology (ESC) and the european society of anaesthesiology (ESA). European heart journal. 2014;35(35):2383-2431.